#HISTORY OF CISPLATIN-Cisplatin is one of a number of platinum coordination complexes with antitumour activity.
#(S1 (S (NP (NP (NN HISTORY)) (PP (IN OF) (NP (NNP CISPLATIN-Cisplatin)))) (VP (AUX is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NN platinum) (NN coordination) (NNS complexes)) (PP (IN with) (NP (JJ antitumour) (NN activity))))))))) (. .)))
#Rule:Nouns
r1HISTORYNN
r1CISPLATIN-CisplatinNNP
r1numberNN
r1platinumNN
r1coordinationNN
r1complexesNNS
r1activityNN

#Rule:Adjs
r4antitumourJJ

#Rule:Adj-Noun
r5antitumourJJactivityNN

#Rule:N-HeadNoun
r8coordinationNNcomplexesNNS
r8platinumNNcomplexesNNS

#Rule:HeadNoun-V
r11HISTORYNNisAUX

#Rule:V-HeadNoun
r21isAUXoneCD

#Rule:PPinNP
r26HISTORYNNofINCISPLATIN-CisplatinNNP
r26oneCDofINnumberNN
r26numberNNofINcomplexesNNS
r26complexesNNSwithINactivityNN

#Rule:IS-RULE
r47oneCDHISTORYNN

# The potential of this compound as an antitumour agent was recognised through an observation made by Barnett Rosenberg and co-workers.
#(S1 (S (NP (NP (DT The) (NN potential)) (PP (IN of) (NP (NP (DT this) (NN compound)) (PP (IN as) (NP (DT an) (NN antitumour) (NN agent)))))) (VP (AUX was) (VP (VBN recognised) (PP (IN through) (NP (NP (DT an) (NN observation)) (VP (VBN made) (PP (IN by) (NP (NP (NNP Barnett) (NNP Rosenberg)) (CC and) (NP (NNS co-workers))))))))) (. .)))
#Rule:Nouns
r1potentialNN
r1compoundNN
r1antitumourNN
r1agentNN
r1observationNN
r1Barnett RosenbergPersonAnnotation
r1co-workersNNS

#Rule:Verbs
r2recognisedVBN
r2madeVBN

#Rule:N-HeadNoun
r8antitumourNNagentNN

#Rule:V-By-Agent
r13Barnett RosenbergPersonAnnotationmadeVBN
r13co-workersNNSmadeVBN

#Rule:V-HeadNoun(passive)
r23recognisedVBNpotentialNN

#Rule:V-HeadNoun(passive)
r24madeVBNobservationNN

#Rule:PPinNP
r26potentialNNofINcompoundNN
r26compoundNNasINagentNN

#Rule:PPinVP
r32recognisedVBNthroughINobservationNN

# Their study had been designed to explore the possible effects of an electric field on the growth of Eschericia coli.
#(S1 (S (NP (PRP$ Their) (NN study)) (VP (AUX had) (VP (AUX been) (VP (VBN designed) (S (VP (TO to) (VP (VB explore) (NP (NP (DT the) (JJ possible) (NNS effects)) (PP (IN of) (NP (DT an) (JJ electric) (NN field))) (PP (IN on) (NP (NP (DT the) (NN growth)) (PP (IN of) (NP (NNP Eschericia) (NNS coli)))))))))))) (. .)))
#Rule:Nouns
r1studyNN
r1effectsNNS
r1fieldNN
r1growthNN
r1Eschericia coliPersonAnnotation

#Rule:Verbs
r2designedVBN
r2exploreVB

#Rule:Adjs
r4possibleJJ
r4electricJJ

#Rule:Adj-Noun
r5possibleJJeffectsNNS
r5electricJJfieldNN

#Rule:PRP-Noun
r6theirPRP$studyNN

#Rule:V-HeadNoun
r21exploreVBeffectsNNS

#Rule:V-HeadNoun(passive)
r23designedVBNstudyNN

#Rule:PPinNP
r26effectsNNSofINfieldNN
r26effectsNNSonINgrowthNN
r26growthNNofINEschericia coliPersonAnnotation

#Rule:V-V
r44designedVBNexploreVB

# They observed the bacteria growing in the form of long filaments, but unexpectedly, they ceased to divide.
#(S1 (S (S (NP (PRP They)) (VP (VBD observed) (NP (NP (DT the) (NNS bacteria)) (VP (VBG growing) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (JJ long) (NNS filaments))))))))) (, ,) (CC but) (S (ADVP (RB unexpectedly)) (, ,) (NP (PRP they)) (VP (VBD ceased) (S (VP (TO to) (VP (VB divide)))))) (. .)))
#Rule:Nouns
r1bacteriaNNS
r1formNN
r1filamentsNNS

#Rule:Verbs
r2observedVBD
r2growingVBG
r2ceasedVBD
r2divideVB

#Rule:Adjs
r4longJJ

#Rule:Adj-Noun
r5longJJfilamentsNNS

#Rule:HeadNoun-V
r11theyPRPobservedVBD
r11bacteriaNNSgrowingVBG
r11theyPRPceasedVBD

#Rule:V-HeadNoun
r21observedVBDbacteriaNNS

#Rule:PPinNP
r26formNNofINfilamentsNNS

#Rule:PPinVP
r30growingVBGinINformNN

#Rule:V-V
r44ceasedVBDdivideVB

#Rule:V-ADV
r46ceasedVBDunexpectedlyRB

# Months of rigorous equipment checks and testing ensued, to try and explain this phenomenon.
#(S1 (S (NP (NP (NNS Months)) (PP (IN of) (NP (NP (JJ rigorous) (NN equipment) (NNS checks)) (CC and) (NP (NN testing))))) (VP (VBD ensued) (, ,) (S (VP (TO to) (VP (VB try) (CC and) (VB explain) (NP (DT this) (NN phenomenon)))))) (. .)))
#Rule:Nouns
r1MonthsNNS
r1equipmentNN
r1checksNNS
r1testingNN
r1phenomenonLocationAnnotation

#Rule:Verbs
r2ensuedVBD
r2tryVB
r2explainVB

#Rule:Adjs
r4rigorousJJ

#Rule:Adj-Noun
r5rigorousJJchecksNNS

#Rule:N-HeadNoun
r8equipmentNNchecksNNS

#Rule:HeadNoun-V
r11MonthsNNSensuedVBD

#Rule:V-HeadNoun
r21tryVBphenomenonLocationAnnotation

#Rule:PPinNP
r26MonthsNNSofINchecksNNS
r26MonthsNNSofINtestingNN

#Rule:V-V
r44ensuedVBDtryVB

# It was not until a year later that the cause of the inhibition of bacterial division was pinpointed to an electrolysis product of the platinum electrode ??. This accidental discovery soon initiated a series of investigations and studies into the effects of platinum compounds and cell division..In 
#(S1 (S (S (NP (PRP It)) (VP (AUX was) (RB not) (PP (IN until) (NP (DT a) (NN year) (RB later))) (SBAR (IN that) (S (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (JJ bacterial) (NN division)))))) (VP (AUX was) (VP (VBN pinpointed) (PP (TO to) (NP (NP (DT an) (NN electrolysis) (NN product)) (PP (IN of) (NP (DT the) (NN platinum) (NN electrode) (NN ??)))))))))) (. .)) (NP (NP (DT This) (JJ accidental) (NN discovery)) (VP (ADVP (RB soon)) (VBN initiated) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (NNS investigations) (CC and) (NNS studies)))) (PP (IN into) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN platinum) (NNS compounds) (CC and) (NN cell) (NN division))))))) (VP (VBZ ..) (NP (NNP In)))))
#Rule:Nouns
r1yearNN
r1causeNN
r1inhibitionNN
r1divisionNN
r1electrolysisNN
r1productNN
r1platinumNN
r1electrodeNN
r1??LocationAnnotation
r1discoveryNN
r1seriesNN
r1investigationsNNS
r1studiesNNS
r1effectsNNS
r1platinumNN
r1compoundsNNS
r1cellNN
r1divisionNN
r1InNNP

#Rule:Verbs
r2pinpointedVBN
r2initiatedVBN
r2..VBZ

#Rule:Adjs
r4bacterialJJ
r4accidentalJJ

#Rule:Adj-Noun
r5bacterialJJdivisionNN
r5accidentalJJdiscoveryNN

#Rule:N-HeadNoun
r8electrolysisNNproductNN
r8electrodeNN??LocationAnnotation
r8platinumNN??LocationAnnotation
r8cellNNdivisionNN

#Rule:N-Noun
r9platinumNNcompoundsNNS

#Rule:HeadNoun-V
r11discoveryNN..VBZ
r11itPRPwasAUX

#Rule:V-HeadNoun
r21initiatedVBNseriesNN
r21..VBZInNNP

#Rule:V-HeadNoun(passive)
r23pinpointedVBNcauseNN

#Rule:V-HeadNoun(passive)
r24initiatedVBNdiscoveryNN

#Rule:PPinNP
r26causeNNofINinhibitionNN
r26inhibitionNNofINdivisionNN
r26productNNofIN??LocationAnnotation
r26seriesNNofINinvestigationsNNS
r26effectsNNSofINdivisionNN

#Rule:PPinVP
r30wasAUXuntilINyearNN

#Rule:PPinVP
r32pinpointedVBNtoTOproductNN
r32initiatedVBNintoINeffectsNNS

#Rule:V-IN-V
r43wasAUXthatINpinpointedVBN

#Rule:V-ADV
r46wasAUXnotRB
r46initiatedVBNsoonRB

#In 1970, further studies performed by Rosenburg and his colleagues revealed that these compounds displayed significant antitumour activity and demonstrated that diamminedichloroplatinum(II), specifically the cis isomer, was extremely effective against sarcoma 180 and L1210 leukemia in mice..
#(S1 (S (PP (IN In) (NP (CD 1970))) (, ,) (NP (JJ further) (NNS studies)) (VP (VBD performed) (SBAR (S (PP (IN by) (NP (NP (NNP Rosenburg)) (CC and) (NP (PRP$ his) (NNS colleagues)))) (VP (VBD revealed) (SBAR (IN that) (S (NP (DT these) (NNS compounds)) (VP (VP (VBD displayed) (NP (JJ significant) (JJ antitumour) (NN activity))) (CC and) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (NP (NN diamminedichloroplatinum)) (PRN (-LRB- -LRB-) (NP (NNP II)) (-RRB- -RRB-))) (, ,) (ADVP (RB specifically)) (NP (DT the) (NN cis) (NN isomer)) (, ,)) (VP (AUX was) (ADJP (RB extremely) (JJ effective)) (PP (IN against) (NP (NP (NN sarcoma) (CD 180)) (CC and) (NP (NP (NNP L1210) (NN leukemia)) (PP (IN in) (NP (NNS mice)))))))))))))) (. .)))) (. .)))
#Rule:Nouns
r1studiesNNS
r1RosenburgPersonAnnotation
r1colleaguesNNS
r1compoundsNNS
r1activityNN
r1diamminedichloroplatinum(IIOrganizationAnnotation
r1cisNN
r1isomerNN
r1sarcomaOrganizationAnnotation
r1L1210NNP
r1leukemiaNN
r1miceNNS

#Rule:Verbs
r2performedVBD
r2revealedVBD
r2displayedVBD
r2demonstratedVBD

#Rule:Adjs
r4furtherJJ
r4significantJJ
r4antitumourJJ
r4effectiveJJ

#Rule:Adj-Noun
r5furtherJJstudiesNNS
r5significantJJactivityNN
r5antitumourJJactivityNN
r5180CDsarcomaOrganizationAnnotation

#Rule:PRP-Noun
r6hisPRP$colleaguesNNS

#Rule:N-HeadNoun
r8cisNNisomerNN
r8L1210NNPleukemiaNN

#Rule:HeadNoun-V
r11studiesNNSperformedVBD
r11compoundsNNSdisplayedVBD
r11compoundsNNSdemonstratedVBD
r11diamminedichloroplatinum(IIOrganizationAnnotationwasAUX
r11isomerNNwasAUX

#Rule:V-HeadNoun
r21displayedVBDactivityNN

#Rule:V-ADJ
r25wasAUXeffectiveJJ

#Rule:PPinNP
r26leukemiaNNinINmiceNNS

#Rule:PPinVP
r30wasAUXagainstINsarcomaOrganizationAnnotation
r30wasAUXagainstINleukemiaNN

#Rule:PPinS
r36performedVBDinIN1970CD
r36revealedVBDbyINRosenburgPersonAnnotation
r36revealedVBDbyINcolleaguesNNS

#Rule:V-IN-V
r43revealedVBDthatINdisplayedVBD
r43revealedVBDthatINdemonstratedVBD
r43demonstratedVBDthatINwasAUX

#The efficacy of the platinum complex as an anticancer agent has now beenestablished in a variety of animal tumour models and in human cancer.
#(S1 (S (NP (NP (DT The) (NN efficacy)) (PP (IN of) (NP (NP (DT the) (NN platinum) (NN complex)) (PP (IN as) (NP (DT an) (NN anticancer) (NN agent)))))) (VP (AUX has) (ADVP (RB now)) (VP (VBN beenestablished) (PP (PP (IN in) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NN animal) (NN tumour) (NNS models))))) (CC and) (PP (IN in) (NP (JJ human) (NN cancer)))))) (. .)))
#Rule:Nouns
r1efficacyNN
r1platinumNN
r1complexNN
r1anticancerNN
r1agentNN
r1varietyNN
r1animalNN
r1tumourNN
r1modelsNNS
r1cancerNN

#Rule:Verbs
r2beenestablishedVBN

#Rule:Adjs
r4humanJJ

#Rule:Adj-Noun
r5humanJJcancerNN

#Rule:N-HeadNoun
r8platinumNNcomplexNN
r8anticancerNNagentNN
r8tumourNNmodelsNNS
r8animalNNmodelsNNS

#Rule:HeadNoun-V
r12efficacyNNbeenestablishedVBN

#Rule:PPinNP
r26efficacyNNofINcomplexNN
r26complexNNasINagentNN
r26varietyNNofINmodelsNNS

#Rule:V-ADV
r46hasAUXnowRB
r46beenestablishedVBNnowRB

# Although a number of platinum complexes have since been developed (eg.
#(S1 (S (SBAR (IN Although) (S (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NN platinum) (NNS complexes)))) (VP (AUX have) (ADVP (RB since)) (VP (AUX been) (VP (VBN developed)))))) (-LRB- -LRB-) (VP (VBZ eg)) (. .)))
#Rule:Nouns
r1numberNN
r1platinumNN
r1complexesNNS

#Rule:Verbs
r2developedVBN
r2egVBZ

#Rule:N-HeadNoun
r8platinumNNcomplexesNNS

#Rule:V-HeadNoun(passive)
r23developedVBNnumberNN

#Rule:PPinNP
r26numberNNofINcomplexesNNS

#Rule:V-ADV
r46haveAUXsinceRB
r46beenAUXsinceRB

#, oxaliplatin and carboplatin), and shown to have antitumour properties, we will be focusing most of our attention on cisplatin.
#(S1 (S (S (VP (VP (, ,) (VBN oxaliplatin) (CC and) (VBN carboplatin) (-RRB- -RRB-)) (, ,) (CC and) (VP (VBN shown) (S (VP (TO to) (VP (AUX have) (NP (JJ antitumour) (NNS properties)))))))) (, ,) (NP (PRP we)) (VP (MD will) (VP (AUX be) (VP (VBG focusing) (NP (NP (JJS most)) (PP (IN of) (NP (PRP$ our) (NN attention)))) (PP (IN on) (NP (NN cisplatin)))))) (. .)))
#Rule:Nouns
r1propertiesNNS
r1attentionNN
r1cisplatinLocationAnnotation

#Rule:Verbs
r2oxaliplatinPersonAnnotation
r2carboplatinVBN
r2shownVBN
r2focusingVBG

#Rule:Adjs
r4antitumourJJ
r4mostJJS

#Rule:Adj-Noun
r5antitumourJJpropertiesNNS

#Rule:PRP-Noun
r6ourPRP$attentionNN

#Rule:HeadNoun-V
r11wePRPfocusingVBG

#Rule:V-HeadNoun
r21haveAUXpropertiesNNS
r21focusingVBGmostJJS

#Rule:PPinNP
r26mostJJSofINattentionNN

#Rule:PPinVP
r30focusingVBGonINcisplatinLocationAnnotation

# Cisplatin or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer and ovarian cancer), lymphomas and germ cell tumors.
#(S1 (S (NP (NP (NN Cisplatin) (CC or) (NN cis-diamminedichloroplatinum)) (PRN (-LRB- -LRB-) (NP (NNP II)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NNP CDDP)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ platinum-based) (JJ chemotherapy) (NN drug)) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (JJ various) (NNS types)) (PP (IN of) (NP (NP (NNS cancers)) (, ,) (PP (VBG including) (NP (NP (NNS sarcomas)) (, ,) (NP (NP (DT some) (NNS carcinomas)) (PRN (-LRB- -LRB-) (NP (NP (JJ e.g.) (JJ small) (NN cell) (NN lung) (NN cancer)) (CC and) (NP (NN ovarian) (NN cancer))) (-RRB- -RRB-))) (, ,) (NP (NNS lymphomas)) (CC and) (NP (JJ germ) (NN cell) (NNS tumors))))))))))))) (. .)))
#Rule:Nouns
r1CisplatinNN
r1cis-diamminedichloroplatinum(II) (CDDPOrganizationAnnotation
r1drugNN
r1typesNNS
r1cancersNNS
r1sarcomasPersonAnnotation
r1carcinomasPersonAnnotation
r1cellNN
r1lungNN
r1cancerNN
r1ovarianNN
r1cancerNN
r1lymphomasPersonAnnotation
r1cellNN
r1tumorsNNS

#Rule:Verbs
r2usedVBN
r2treatVB
r2includingVBG

#Rule:Adjs
r4platinum-basedJJ
r4chemotherapyJJ
r4variousJJ
r4e.g.LocationAnnotation
r4smallJJ
r4germJJ

#Rule:Adj-Noun
r5platinum-basedJJdrugNN
r5chemotherapyJJdrugNN
r5variousJJtypesNNS
r5e.g.LocationAnnotationcancerNN
r5smallJJcancerNN
r5germJJtumorsNNS

#Rule:N-HeadNoun
r8lungNNcancerNN
r8cellNNcancerNN
r8ovarianNNcancerNN
r8cellNNtumorsNNS

#Rule:N-ApposN
r10sarcomasPersonAnnotationcarcinomasPersonAnnotation

#Rule:HeadNoun-V
r11CisplatinNNisAUX

#Rule:V-HeadNoun
r21isAUXdrugNN
r21treatVBtypesNNS

#Rule:V-HeadNoun(passive)
r24usedVBNdrugNN

#Rule:PPinNP
r26typesNNSofINcancersNNS

#Rule:V-V
r44usedVBNtreatVB

#Rule:IS-RULE
r47drugNNCisplatinNN

# It was the first member of its class, which now also includes carboplatin and oxaliplatin..As 
#(S1 (S (NP (PRP It)) (VP (AUX was) (NP (NP (DT the) (JJ first) (NN member)) (PP (IN of) (NP (NP (PRP$ its) (NN class)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB now)) (ADVP (RB also)) (VP (VBZ includes) (NP (FW carboplatin) (CC and) (FW oxaliplatin) (FW ..) (NNP As)))))))))))
#Rule:Nouns
r1memberNN
r1classNN
r1oxaliplatin..AsOrganizationAnnotation

#Rule:Verbs
r2includesVBZ

#Rule:Adjs
r4firstJJ

#Rule:Adj-Noun
r5firstJJmemberNN

#Rule:PRP-Noun
r6itsPRP$classNN

#Rule:HeadNoun-V
r11itPRPwasAUX

#Rule:HeadNoun-(who/that)-V
r14classNNincludesVBZ

#Rule:V-HeadNoun
r21wasAUXmemberNN
r21includesVBZoxaliplatin..AsOrganizationAnnotation

#Rule:PPinNP
r26memberNNofINclassNN

#Rule:V-ADV
r46includesVBZnowRB
r46includesVBZalsoRB

#As a compound cisplatin was first described by M. Peyrone in 1845 (known as Peyrone s salt). The structure was elucidated by Alfred Werner in 1893. It was rediscovered in the 1960s by Rosenberg and van Campet al, who discovered that electrolysis products from a platinum electrode inhibited mitosis in Escherichia coli (E. coli) bacteria. The bacteria grow to 300 times their normal length but cell division fails..
#(S1 (S (SBAR (IN As) (S (NP (DT a) (NN compound) (NN cisplatin)) (VP (AUX was) (ADVP (RB first)) (VP (VBN described) (PP (IN by) (NP (NNP M.) (NNP Peyrone))) (PP (IN in) (NP (NP (CD 1845)) (PRN (-LRB- -LRB-) (VP (VBN known) (PP (IN as) (NP (NNP Peyrone) (NNP s) (NN salt)))) (-RRB- -RRB-)) (. .))))))) (NP (DT The) (NN structure)) (VP (AUX was) (VP (VBN elucidated) (PP (IN by) (NP (NNP Alfred) (NNP Werner))) (PP (IN in) (S (VP (VBG 1893.) (SBAR (S (NP (PRP It)) (VP (AUX was) (VP (VBN rediscovered) (PP (IN in) (NP (DT the) (NNS 1960s))) (PP (IN by) (NP (NP (NNP Rosenberg)) (CC and) (NP (NP (NN van) (NNP Campet) (NNP al)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD discovered) (SBAR (S (IN that) (NP (NP (NN electrolysis) (NNS products)) (PP (IN from) (NP (DT a) (NN platinum) (NN electrode)))) (VP (VBD inhibited) (SBAR (S (NP (NP (NNS mitosis)) (PP (IN in) (NP (NP (NNP Escherichia) (NNS coli)) (PRN (-LRB- -LRB-) (NP (NNP E.) (NNS coli)) (-RRB- -RRB-))))) (VP (VBD bacteria.) (SBAR (S (NP (DT The) (NNS bacteria)) (VP (VBP grow) (PP (TO to) (NP (CD 300) (NNS times))) (SBAR (S (NP (PRP$ their) (JJ normal) (NN length) (CC but) (NN cell) (NN division)) (VP (VBZ fails))))))))))) (. .)))))))))))))))))) (. .)))
#Rule:Nouns
r1compoundNN
r1cisplatinNN
r1M. PeyronePersonAnnotation
r1Peyrone sPersonAnnotation
r1saltNN
r1structureNN
r1Alfred WernerPersonAnnotation
r11960sNNS
r1RosenbergPersonAnnotation
r1van CampetPersonAnnotation
r1alNNP
r1electrolysisNN
r1productsNNS
r1platinumNN
r1electrodeNN
r1mitosisNNS
r1EscherichiaLocationAnnotation
r1coliNNS
r1E. coliLocationAnnotation
r1bacteriaNNS
r1timesNNS
r1lengthNN
r1cellNN
r1divisionNN

#Rule:Verbs
r2describedVBN
r2knownVBN
r2elucidatedVBN
r21893VBG
r2rediscoveredVBN
r2discoveredVBD
r2inhibitedVBD
r2bacteriaVBD
r2growVBP
r2failsVBZ

#Rule:Adjs
r4normalJJ

#Rule:Adj-Noun
r5300CDtimesNNS
r5normalJJdivisionNN

#Rule:PRP-Noun
r6theirPRP$divisionNN

#Rule:N-HeadNoun
r8compoundNNcisplatinNN
r8Peyrone sPersonAnnotationsaltNN
r8van CampetPersonAnnotationalNNP
r8electrolysisNNproductsNNS
r8platinumNNelectrodeNN
r8EscherichiaLocationAnnotationcoliNNS
r8cellNNdivisionNN

#Rule:HeadNoun-V
r11productsNNSinhibitedVBD
r11mitosisNNSbacteriaVBD
r11bacteriaNNSgrowVBP
r11divisionNNfailsVBZ

#Rule:V-By-Agent
r13M. PeyronePersonAnnotationdescribedVBN
r13Alfred WernerPersonAnnotationelucidatedVBN
r13RosenbergPersonAnnotationrediscoveredVBN
r13alNNPrediscoveredVBN

#Rule:HeadNoun-(who/that)-V
r14alNNPdiscoveredVBD

#Rule:V-HeadNoun(passive)
r23elucidatedVBNstructureNN
r23describedVBNcisplatinNN
r23rediscoveredVBNitPRP

#Rule:PPinNP
r26productsNNSfromINelectrodeNN
r26mitosisNNSinINcoliNNS

#Rule:PPinVP
r30growVBPtoTOtimesNNS

#Rule:PPinVP
r32describedVBNinIN1845CD
r32knownVBNasINsaltNN
r32rediscoveredVBNinIN1960sNNS

#Rule:V-ADV
r46wasAUXfirstRB
r46describedVBNfirstRB

#In the 1970s, a series of experiments were conducted at Michigan State University to test the effects the cis-diamminedichloroplatinum(II), along with other platinum coordination complexes, on sarcomas artificially implanted in rats. This study found that cis-diamminedichloroplatinum(II) was the most effective out of this group, which started the medicinal career of cisplatin-.
#(S1 (S (PP (IN In) (NP (DT the) (CD 1970s))) (, ,) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (NNS experiments)))) (VP (AUX were) (VP (VBN conducted) (PP (IN at) (NP (NNP Michigan) (NNP State) (NNP University))) (S (VP (TO to) (VP (VB test) (NP (DT the) (NNS effects)) (NP (NP (DT the) (NN cis-diamminedichloroplatinum)) (PRN (-LRB- -LRB-) (NP (NNP II)) (-RRB- -RRB-))) (, ,) (ADVP (IN along) (PP (IN with) (NP (JJ other) (NN platinum) (NN coordination) (NNS complexes)))) (, ,) (PP (IN on) (NP (NP (NNS sarcomas)) (VP (ADVP (RB artificially)) (VBN implanted) (PP (IN in) (NP (NP (NN rats.)) (SBAR (S (NP (DT This) (NN study)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NN cis-diamminedichloroplatinum)) (PRN (-LRB- -LRB-) (NP (NNP II)) (-RRB- -RRB-))) (VP (AUX was) (NP (NP (DT the) (RBS most) (JJ effective)) (PP (IN out) (PP (IN of) (NP (NP (DT this) (NN group)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD started) (NP (NP (DT the) (JJ medicinal) (NN career)) (PP (IN of) (NP (NN cisplatin-))))))))))))))))))))))))))) (. .)))
#Rule:Nouns
r1seriesNN
r1experimentsNNS
r1Michigan State UniversityOrganizationAnnotation
r1effectsNNS
r1cis-diamminedichloroplatinumPersonAnnotation
r1IINNP
r1platinumNN
r1coordinationNN
r1complexesNNS
r1sarcomasNNS
r1ratsNN
r1studyNN
r1cis-diamminedichloroplatinum(IIOrganizationAnnotation
r1groupNN
r1careerNN
r1cisplatin-NN

#Rule:Verbs
r2conductedVBN
r2testVB
r2implantedVBN
r2foundVBD
r2startedVBD

#Rule:Adjs
r4otherJJ
r4effectiveJJ
r4medicinalJJ

#Rule:Adj-Noun
r5otherJJcomplexesNNS
r5medicinalJJcareerNN

#Rule:N-HeadNoun
r8coordinationNNcomplexesNNS
r8platinumNNcomplexesNNS

#Rule:HeadNoun-V
r11studyNNfoundVBD
r11cis-diamminedichloroplatinum(IIOrganizationAnnotationwasAUX

#Rule:HeadNoun-(who/that)-V
r14groupNNstartedVBD

#Rule:NP(NP(z) SBAR(S(NP(x)VP(y))))
r19foundVBDratsNN

#Rule:V-HeadNoun
r21testVBeffectsNNS
r21testVBcis-diamminedichloroplatinumPersonAnnotation
r21wasAUXeffectiveJJ
r21startedVBDcareerNN

#Rule:V-HeadNoun(passive)
r23conductedVBNseriesNN

#Rule:V-HeadNoun(passive)
r24implantedVBNsarcomasNNS

#Rule:PPinNP
r26seriesNNofINexperimentsNNS
r26careerNNofINcisplatin-NN

#Rule:PPComboInNP
r27effectiveJJoutINgroupNN

#Rule:PPinVP
r30testVBonLocationAnnotationsarcomasNNS

#Rule:PPinVP
r32conductedVBNatINMichigan State UniversityOrganizationAnnotation
r32implantedVBNinINratsNN

#Rule:PPinS
r36wereAUXinIN1970sCD

#Rule:V-IN-V
r43foundVBDthatINwasAUX

#Rule:V-V
r44conductedVBNtestVB

#Rule:V-ADV
r46implantedVBNartificiallyRB

#Rule:IS-RULE
r47effectiveJJcis-diamminedichloroplatinum(IIOrganizationAnnotation

@lemmas-left	compound	developed	conducted	Barnett Rosenberg	equipment	Eschericia coli	checks	its	phenomenon	ceased	1893.	year	rigorous	mitosis	cis-diamminedichloroplatinum(II) (CDDP	cell	demonstrated	shown	number	effects	colleagues	further	models	observed	beenestablished	carboplatin	implanted	explain	discovery	try	we	Alfred Werner	complex	fails	coordination	implant	made	use	designed	division	significant	experiments	elucidated	times	Michigan State University	1960s	Months	member	compounds	anticancer	cis-diamminedichloroplatinum	divide	tumor	history	field	180	eg	lung	including	sarcomas	testing	discovered	cancer	L1210	complexes	normal	revealed	perform	long	l1210	has	conduct	be	300	demonstrate	cisplatin-cisplatin	recognised	electric	Rosenberg	display	efficacy	oxaliplatin	agent	ensued	investigations	electrode	platinum	sarcoma	make	co-workers	salt	mouse	model	possible	accidental	types	attention	activity	animal	cease	colleague	filament	isomer	variety	cancers	al	grow	electrolysis	our	growth	they	pinpoint	test	fail	E. coli	initiate	describe	initiated	inhibit	focus	Escherichia	HISTORY	structure	1893	form	career	rats.	carcinomas	include	displayed	start	performed	month	small	cis-diamminedichloroplatinum(II	series	most	tumors	effective	Rosenburg	leukemia	length	products	bacterial	oxaliplatin..As	observation	product	filaments	bacteria	ovarian	medicinal	e.g.	rediscovered	design	based	described	rediscover	recognise	reveal	cause	pinpointed	study	show	inhibited	studies	type	used	elucidate	been	mice	??	were	antitumour	his	experiment	..	coli	investigation	bacteria.	II	inhibition	germ	discover	class	property	properties	ensue	chemotherapy	M. Peyrone	known	treat	diamminedichloroplatinum(II	explore	van Campet	other	cisplatin-	In	lymphomas	have	one	Peyrone s	focusing	co-worker	includes	was	Cisplatin	cis	various	develop	cisplatin	rats	drug	CISPLATIN-Cisplatin	is	it	check	tumour	ii	potential	growing	in	know	human	platinum-based	observe	started	group	their	first	found	
@lemmas-right	compound	pinpoint	test	Eschericia coli	checks	phenomenon	1970	ceased	fail	describe	inhibit	year	focus	HISTORY	structure	form	career	demonstrated	number	effects	rats.	colleagues	carcinomas	include	not	models	observed	beenestablished	displayed	start	unexpectedly	now	performed	discovery	try	cis-diamminedichloroplatinum(II	series	complex	fails	made	most	tumors	effective	Rosenburg	division	experiments	elucidated	times	Michigan State University	1960s	leukemia	1970s	products	1845	oxaliplatin..As	member	observation	compounds	cis-diamminedichloroplatinum	divide	tumor	product	history	field	filaments	bacteria	sarcomas	testing	artificially	rediscovered	discovered	cancer	described	rediscover	complexes	cause	pinpointed	study	perform	inhibited	since	studies	type	elucidate	mice	??	experiment	..	coli	investigation	bacteria.	be	demonstrate	cisplatin-cisplatin	inhibition	discover	class	display	property	properties	agent	ensue	ensued	electrode	investigations	sarcoma	make	salt	treat	explore	mouse	model	cisplatin-	In	one	focusing	includes	was	Cisplatin	cisplatin	types	rats	attention	activity	drug	CISPLATIN-Cisplatin	is	it	check	cease	potential	colleague	growing	filament	in	soon	isomer	cancers	al	observe	grow	started	group	first	also	found	growth	
@lemmas-center	to	with	at	into	as	by	through	from	in	until	of	that	against	on	out	